{"id":"NCT02118961","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents","officialTitle":"Confirmatory Study to Evaluate the Immunogenicity of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP Vaccine, BK1301) as a Booster in Adolescents","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04","primaryCompletion":"2014-08","completion":"2014-08","firstPosted":"2014-04-21","resultsPosted":"2016-11-21","lastUpdate":"2017-01-13"},"enrollment":446,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Diphtheria","Tetanus","Pertussis"],"interventions":[{"type":"BIOLOGICAL","name":"Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)","otherNames":["TRIBIK®"]},{"type":"BIOLOGICAL","name":"Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)","otherNames":["DTBIK®"]}],"arms":[{"label":"BK1301","type":"EXPERIMENTAL"},{"label":"DT toxoid","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to assess the immunogenicity and safety of DTaP vaccine (BK1301) as a booster dose in adolescents.\n\nThe purposes of this study are as follows:\n\n* To confirm the non-inferiority of BK1301 to Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid) with respect to booster responses for anti-diphtheria toxoid (anti-D) and anti-tetanus toxoid (anti-T) antibodies\n* To confirm that booster responses for anti-pertussis toxoid (anti-PT) and anti-Filamentous Hemagglutinin (anti-FHA) antibodies are more than 80% of participants received BK1301","primaryOutcome":{"measure":"Percentage of Participants With Booster Responses for Anti-diphtheria Toxoid (Anti-D) and Anti-tetanus Toxoid (Anti-T) Antibodies","timeFrame":"pre-vaccination and 28-42 days after vaccination","effectByArm":[{"arm":"BK1301","deltaMin":100,"sd":null},{"arm":"DT Toxoid","deltaMin":99.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"11 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":7,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":223},"commonTop":["Injection site erythema","Injection site swelling","Injection site pruritus","Injection site pain","Injection site warmth"]}}